EASL 2023 – Biomarkers back a new NASH player

Hard NASH endpoint results with 89Bio’s pegozafermin, released at the Easl meeting today, do not add much to what was toplined in March. A new cut of biomarker data are more interesting – not for what they show about 89Bio’s project, but for the light they shed on a mechanistically similar candidate from a private group: Boston Pharmaceuticals.